LpMab-23: A Cancer-Specific Monoclonal Antibody Against Human Podoplanin

Shinji Yamada, Satoshi Ogasawara, Mika K. Kaneko, Yukinari Kato

Research output: Contribution to journalArticle

23 Citations (Scopus)

Abstract

Human podoplanin (hPDPN), the ligand of C-type lectin-like receptor-2, is involved in cancer metastasis. Until now, many monoclonal antibodies (mAbs) have been established against hPDPN. However, it is still difficult to develop a cancer-specific mAb (CasMab) against hPDPN because the protein sequence of hPDPN expressed in cancer cells is the same as that in normal cells. Herein, we report LpMab-23 of the mouse IgG1 subclass, a novel CasMab against hPDPN. In an immunohistochemical analysis, LpMab-23 reacted with tumor cells of human oral cancer, but did not react with normal cells such as lymphatic endothelial cells (LECs). In contrast, LpMab-17, another anti-hPDPN mAb, reacted with both tumor cells and LECs. Furthermore, flow cytometric analysis revealed that LpMab-23 reacted with hPDPN-expressing cancer cell lines (LN319, RERF-LC-AI/hPDPN, Y-MESO-14/hPDPN, and HSC3/hPDPN) but showed little reaction with normal cells (LECs and HEK-293T), although another anti-hPDPN mAb, LpMab-7, reacted with both hPDPN-expressing cancer cells and normal cells, indicating that LpMab-23 is a CasMab against hPDPN.

Original languageEnglish
Pages (from-to)72-76
Number of pages5
JournalMonoclonal antibodies in immunodiagnosis and immunotherapy
Volume36
Issue number2
DOIs
Publication statusPublished - 2017 Apr

Keywords

  • CasMab
  • cancer-specific antibody
  • monoclonal antibody
  • podoplanin

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology

Fingerprint Dive into the research topics of 'LpMab-23: A Cancer-Specific Monoclonal Antibody Against Human Podoplanin'. Together they form a unique fingerprint.

  • Cite this